Fred Alger Management’s Cue Biopharma CUE Stock Holding History

Fred Alger Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-133	Closed	-$57K	–	519
2020 Q1	$57K	Buy	+133	New	+$64.5K	﹤0.01%	414

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fred Alger Management's CUE Position: Q2 2020 in Review

Fred Alger Management sold out of Cue Biopharma (CUE) in Q2 2020, closing a stake of 133 shares — an estimated $57K sold.

Fred Alger Management first reported a position in CUE in Q1 2020 and held it in 1 quarter. The position peaked at $57K in Q1 2020. 99 funds tracked by Wall St. Rank hold CUE as of Q2 2020.

Fred Alger Management reported no remaining Cue Biopharma position as of Q2 2020 after selling out during the quarter.
Fred Alger Management sold 133 Cue Biopharma shares in Q2 2020, an estimated $57K.
Fred Alger Management first reported a position in Cue Biopharma in Q1 2020 and held it in 1 quarter.
Fred Alger Management's Cue Biopharma position peaked at $57K in Q1 2020.
99 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2020.

Based on Fred Alger Management's 13F filing for Q2 2020, filed 14 Aug 2020.